Clonally related Neisseria gonorrhoeae isolates with decreased susceptibility to the extended-spectrum cephalosporin cefotaxime in Amsterdam, the Netherlands

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1516-1522

  Heymans, Raymond ^a   Bruisten, Sylvia M ^a,b   Golparian, Daniel ^c   Unemo, Magnus ^c   De Vries, Henry J C ^a,b,d   Van Dama, Alje P ^a,e  

^a Health Service Amsterdam   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; PENICILLIN BINDING PROTEIN 2A;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL VARIATION; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; GENE DELETION; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; NETHERLANDS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TREATMENT FAILURE; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; ALLELES; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEPHALOSPORIN RESISTANCE; CLONE CELLS; FEMALE; GONORRHEA; HUMANS; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MOSAICISM; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; NETHERLANDS; PHYLOGENY; SEQUENCE ANALYSIS, DNA;

EID: 84857185363     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05481-11     Document Type: Article

References (38)

1. Allen VG, et al. 2011. Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob. Agents Chemother. 55:703-712.
2. Ameyama S, et al. 2002. Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob. Agents Chemother. 46:3744-3749. (Pubitemid 35403246)
3. Barry PM, Klausner JD. 2009. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert. Opin. Pharmacother. 10:555-577.
4. Bignell C. 2009. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int. J. STD AIDS 20:453-457.
5. Centers for Disease Control and Prevention (CDC). 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR Morb. Mortal. Wkly. Rep. 60:873-877.
6. Deguchi T, Yasuda M, Maeda S. 2008. Lack of nationwide surveillance of antimicrobial resistance of Neisseria gonorrhoeae in Japan. Ann. Intern. Med. 149:363-364.
7. de Vries HJ, van der Helm JJ, Schim van der Loeff MF, van Dam AP. 2009. Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. Euro Surveill. 14(37):pii=19330.
8. Domain Group for Sexually Transmitted Infections (NVDV). 2009. Diagnostics and treatment of sexually transmitted infections, version 2008/2009. SoaAids, Amsterdam, the Netherlands. http://www.soaaids -professionals.nl/ medische-richtlijnen/nvdv. (In Dutch.)
9. Florindo C, et al. 2010. Genotypes and antimicrobial-resistant phenotypes of Neisseria gonorrhoeae in Portugal (2004-2009). Sex. Transm. Infect. 86:449-453.
10. Golparian D, Hellmark B, Fredlund H, Unemo M. 2010. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex. Transm. Infect. 86:454-460.
11. Heijman TL, et al. 2007. Effectiveness of a risk-based visitor-prioritizing system at a sexually transmitted infection outpatient clinic. Sex. Transm. Dis. 34:508-512. (Pubitemid 46987960)
12. Heymans R, Schouls LM, van der Heide HG, van der Loeff MF, Bruisten SM. 2011. Multiple-locus variable-number tandem repeat analysis of Neisseria gonorrhoeae. J. Clin. Microbiol. 49:354-363.
13. Huang CT, et al. 2010. Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan. Antimicrob. Agents Chemother. 54:4893-4895.
14. Ito M, et al. 2005. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob. Agents Chemother. 49:137-143. (Pubitemid 40065784)
15. Lee SG, et al. 2010. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J. Antimicrob. Chemother. 65:669-675.
16. Lewis DA. 2010. The Gonococcus fights back: is this time a knock out? Sex. Transm. Infect. 86:415-421.
17. Lindberg R, Fredlund H, Nicholas R, Unemo M. 2007. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob. Agents Chemother. 51:2117-2122. (Pubitemid 46903103)
18. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. 2004. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J. Infect. Dis. 189:1497-1505. (Pubitemid 38552358)
19. Moran JS. 1995. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex. Transm. Dis. 22:39-47.
20. Ohnishi M, et al. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55:3538-3545.
21. Ohnishi M, et al. 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg. Infect. Dis. 17:148-149.
22. Pandori M, et al. 2009. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob. Agents Chemother. 53:4032-4034.
23. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. 2006. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 50:3638-3645. (Pubitemid 44684875)
24. Tapsall JW. 2009. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr. Opin. Infect. Dis. 22:87-91.
25. Tapsall JW, Ndowa F, Lewis DA, Unemo M. 2009. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert. Rev. Anti. Infect. Ther. 7:821-834.
26. Tapsall JW, Ray S, Limnios A. 2010. Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolates collected in Sydney, Australia, in 2007-2008. Antimicrob. Agents Chemother. 54:554-556.
27. Tomberg J, Unemo M, Davies C, Nicholas RA. 2010. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 49:8062-8070.
28. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. 2009. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63:1142-1151.
29. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 16(6):pii=19792.
30. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 2010. Two cases of verified clinical failures using internationally recommended firstline cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 15(47):pii=19721.
31. Unemo M, et al. 2007. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacinresistant strain. APMIS 115:231-241.
32. Whiley D, et al. 2007. Use of a novel screening PCR indicates presence of Neisseria gonorrhoeae isolates with a mosaic penA gene sequence in Australia. Pathology 39:445-446. (Pubitemid 47221473)
33. Whiley DM, et al. 2010. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J. Antimicrob. Chemother. 65:1615-1618.
34. Whiley DM, et al. 2010. Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J. Antimicrob. Chemother. 65:2543-2547.
35. Workowski KA, Berman SM, Douglas JM, Jr. 2008. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann. Intern. Med. 148:606-613. (Pubitemid 351669134)
36. Xia M, Whittington WL, Shafer WM, Holmes KK. 2000. Gonorrhea among men who have sex with men: outbreak caused by a single genotype of erythromycin-resistant Neisseria gonorrhoeae with a single-base pair deletion in the mtrR promoter region. J. Infect. Dis. 181:2080-2082. (Pubitemid 30416180)
37. Yokoi S, et al. 2007. Threat to cefixime treatment for gonorrhea. Emerg. Infect. Dis. 13:1275-1277.
38. Zhao S, et al. 2009. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 53:3744-3751.